Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Discovery & Translation

Ring’s immune-evading anelloviruses; plus Tenaya, Goldfinch and Coagulant 

BioCentury’s roundup of translational news

July 8, 2022 8:34 PM UTC

Ring Therapeutics Inc. shared in a bioRxiv preprint a structural analysis of anelloviruses, which are being developed by Ring as gene therapy vectors in cancer, hematology and inflammation indications, shedding light on their immune evading properties. The authors discovered surface features that render the particles less susceptible to antibody neutralization.

Anelloviruses’ potential to evade the immune system could overcome limitations in re-dosing and durability that hamper other gene therapy vectors, including adeno-associated viruses (AAVs) and lentiviruses...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article